Cargando…
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments....
Autores principales: | Thouvenin, J., Van Marcke, C., Decoster, L., Raicevic, G., Punie, K., Vandenbulcke, M., Salgado, R., Van Valckenborgh, E., Maes, B., Joris, S., Steichel, D. Vander, Vranken, K., Jacobs, S., Dedeurwaerdere, F., Martens, G., Devos, H., Duhoux, F.P., Rasschaert, M., Pauwels, P., Geboes, K., Collignon, J., Tejpar, S., Canon, J.-L., Peeters, M., Rutten, A., Van de Mooter, T., Vermeij, J., Schrijvers, D., Demey, W., Lybaert, W., Van Huysse, J., Mebis, J., Awada, A., Claes, K.B.M., Hebrant, A., Van der Meulen, J., Delafontaine, B., Bempt, I. Vanden, Maetens, J., de Hemptinne, M., Rottey, S., Aftimos, P., De Grève, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434164/ https://www.ncbi.nlm.nih.gov/pubmed/35970014 http://dx.doi.org/10.1016/j.esmoop.2022.100524 |
Ejemplares similares
-
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future
por: Geukens, T., et al.
Publicado: (2022) -
Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer
por: Roeyen, G., et al.
Publicado: (2022) -
Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium
por: Van Valckenborgh, Els, et al.
Publicado: (2018) -
Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model
por: Menu, E, et al.
Publicado: (2004) -
Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma
por: Caers, J, et al.
Publicado: (2008)